Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation …

bevacizumab
nephrectomy
tumor cells
neutrophil count
ct scan
  • 8 views
  • 24 Jan, 2021
  • 1 location
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) in people with metastatic kidney cancer.

cabozantinib
clear cell renal cell carcinoma
ovarian suppression
nivolumab
measurable disease
  • 61 views
  • 28 Jan, 2021
  • 8 locations
A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and low dose anti-PD-1 antibody in patients with metastatic renal cell carcinoma

  • 20 views
  • 22 Jan, 2021
  • 1 location
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

The purpose of this research study is to see what effect the combination of lenvatinib plus everolimus has in local and metastatic renal cell carcinoma to potentially make surgically

angiogenesis
VEGFR2
everolimus
neutrophil count
cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

This Single-arm, multicentre, phase 2 trial aims determine the activity and safety of pembrolizumab and denosumab in advanced clear cell renal cell carcinoma (ccRCC).

clear cell renal cell carcinoma
pembrolizumab
neutrophil count
liver metastasis
carcinoma
  • 492 views
  • 04 Feb, 2021
  • 17 locations
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies

antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in patients with metastatic renal cell carcinoma (RCC) and to compare qualitatively with conventional imaging response

angiogenesis
nephrectomy
tumor cells
ct scan
cancer
  • 3 views
  • 28 Jan, 2021
  • 1 location
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

The primary objective of this single arm phase 2 trial is to assess the response rate [complete response (CR) + partial response (PR)] of combined nivolumab and HD IL-2 in subjects with metastatic melanoma and renal cell carcinoma. Response will be performed after each course of nivolumab and IL-2 using …

interleukin 2
nivolumab
direct bilirubin
vasectomy
measurable disease
  • 33 views
  • 25 Jan, 2021
  • 1 location
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.

Patients with advanced cancers who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immunotherapy. The pleura also acts as a natural barrier that can limit the penetration of immune checkpoint inhibitors. In this multicenter phase 2 study, the preliminary efficacy and toxicity of intrapleural …

  • 0 views
  • 22 Feb, 2021
  • 5 locations
UCDCC#272: IL-2 Radiotherapy and Pembrolizumab in Patients Refractory to Checkpoint Blockade

This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 / PD-L1 checkpoint blockade therapy will be enrolled. Patients must have a candidate treatment …

pd-l1
interleukin 2
pembrolizumab
stage iv non-small cell lung cancer
interleukin-2
  • 25 views
  • 24 Jan, 2021
  • 2 locations
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma

Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the consultation as part of their usual care. The patients will be included before Sunitinib treatment is started. …

treatment regimen
sunitinib
kidney cancer
cancer
liver metastasis
  • 0 views
  • 25 Jan, 2021
  • 1 location